jesse, I respect your opinions but ... in the interest of accuracy ...
The money GTC owes is not even pocket change for GE. Leo could probably walk away from ATryn and save money at this point. I suppose Merrimac is dependent for their product, but GTC does not provide product for LFB or Pharmathene (for Protexia). The LFB collaborations are all still pre-clinical and Pharmathene receives only consulting services from GTC. (Pharmathene has their own goat herd.)
Maybe Merrimac will pull GTC's chestnuts out of the fire.